Project 2: Muscular dystrophy clinical trial foundations. Substantial evidence implicates aberrant reactivation of DUX4 expression as the cause of facioscapulohumeral dystrophy (FSHD). Expression profiling of primary myoblasts transduced with DUX4 has identified DUX4 regulated genes, many of which are involved in germline and early stem cell development. Many of these genes are expressed in FSHD muscle but not in muscle from healthy controls, making them ideal biomarker candidates. As FSHD research enters a translational phase, the development of mechanistic, prognostic, and diagnostic biomarkers becomes critical in moving the translational process forward.
Aim 1 is a cooperative clinical study for biomarker evaluation in FSHD that will (a) develop FSHD patient registration, assessments, and sample collection in Seattle that parallel those developed in Rochester;(b) develop FSHD MRI assessment capabilities in Rochester that parallel those developed in Seattle;and (c) perform a focused collaborative clinical study to determine the molecular determinants of the MRI findings characteristic of FSHD and to prioritize the best candidate biomarkers for disease activity.
Aim 2 will determine whether CD8+ T cells infiltrating FSHD muscle recognize DUX4 induced cancer/testes (C/T) antigens, and will (a) characterize the phenotype, location, and cytokine profile of the T cell/immune cell infiltrate in skeletal muscle in FSHD;(b) expand T cells from FSHD muscle, determine the T cell receptor Vb gene usage and characterize their function;and (c) determine whether T cells derived from FSHD muscle recognize FSHD muscle antigens. These combined aims represent a synergistic effort to evaluate the relationship between tissue biomarkers, histopathology, MRI imaging characteristics, and muscle function, together with a direct characterization of the T cell infiltrate the immune response in the pathophysiology of FSHD.

Public Health Relevance

This project relates to the broad scope of the Center because it develops the clinical infrastructure necessary for future gene therapy trials in Duchenne and FSHD dystrophies at the University of Washington, and for future inter-institutional trials in muscular dystrophies. In addition it provides a rich translational clinical research program for the Investigator Development and Patient Outreach Core and it uses vectors produced by the Scientific Research Resource Core

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54AR065139-01A1
Application #
8736366
Study Section
Special Emphasis Panel (ZAR1-KM (M1))
Project Start
Project End
Budget Start
2014-05-07
Budget End
2015-04-30
Support Year
1
Fiscal Year
2014
Total Cost
$502,016
Indirect Cost
$53,703
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Lawlor, Michael W; Beggs, Alan H; Buj-Bello, Ana et al. (2016) Skeletal Muscle Pathology in X-Linked Myotubular Myopathy: Review With Cross-Species Comparisons. J Neuropathol Exp Neurol 75:102-10
Bengtsson, Niclas E; Seto, Jane T; Hall, John K et al. (2016) Progress and prospects of gene therapy clinical trials for the muscular dystrophies. Hum Mol Genet 25:R9-17
Kolwicz Jr, Stephen C; Odom, Guy L; Nowakowski, Sarah G et al. (2016) AAV6-mediated Cardiac-specific Overexpression of Ribonucleotide Reductase Enhances Myocardial Contractility. Mol Ther 24:240-50
Su, Wei; Kang, John; Sopher, Bryce et al. (2016) Recombinant adeno-associated viral (rAAV) vectors mediate efficient gene transduction in cultured neonatal and adult microglia. J Neurochem 136 Suppl 1:49-62
Macadangdang, Jesse; Guan, Xuan; Smith, Alec S T et al. (2015) Nanopatterned Human iPSC-based Model of a Dystrophin-Null Cardiomyopathic Phenotype. Cell Mol Bioeng 8:320-332
Ramos, Julian; Chamberlain, Jeffrey S (2015) Gene Therapy for Duchenne muscular dystrophy. Expert Opin Orphan Drugs 3:1255-1266
Bisset, Darren R; Stepniak-Konieczna, Ewa A; Zavaljevski, Maja et al. (2015) Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy. Hum Mol Genet 24:4971-83
Guan, Xuan; Wang, Zejing; Czerniecki, Stefan et al. (2015) Use of Adeno-Associated Virus to Enrich Cardiomyocytes Derived from Human Stem Cells. Hum Gene Ther Clin Dev 26:194-201
Hollinger, Katrin; Chamberlain, Jeffrey S (2015) Viral vector-mediated gene therapies. Curr Opin Neurol 28:522-7
Cheever, Thomas R; Berkley, Dale; Braun, Serge et al. (2015) Perspectives on best practices for gene therapy programs. Hum Gene Ther 26:127-33

Showing the most recent 10 out of 11 publications